Medicine and Health

A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction

M. Ejeme, Q. Li, et al.

This groundbreaking research unveils MAb362, a cross-reactive human IgA monoclonal antibody that tackles both SARS-CoV and SARS-CoV-2 spike proteins, effectively blocking ACE2 receptor binding. With the potential to neutralize SARS-CoV-2, this study suggests that specific IgA antibodies could be key in boosting mucosal immunity. Conducted by a team of experts, including Monir Ejeme and Qi Li, this work sheds light on new avenues for COVID-19 defense.